{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:46:54Z","timestamp":1791406014572,"version":"4.3.3"},"reference-count":96,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Although the mechanisms of action (MoA) of nonstructural protein 3 inhibitors (NS3i) and NS5B inhibitors (NS5Bi) are well understood, the MoA of cyclophilin inhibitors (CypI) and NS5A inhibitors (NS5Ai) are not fully defined. In this study, we examined whether CypI and NS5Ai interfere with hepatitis C virus (HCV) RNA synthesis of replication complexes (RCs) or with an earlier step of HCV RNA replication, the creation of double-membrane vesicles (DMVs) essential for HCV RNA replication. In contrast to NS5Bi, both CypI and NS5Ai do not block HCV RNA synthesis by way of RCs, suggesting that they exert their antiviral activity prior to the establishment of enzymatically active RCs. We found that viral replication is not a precondition for DMV formation, since the NS3-NS5B polyprotein or NS5A suffices to create DMVs. Importantly, only CypI and NS5Ai, but not NS5Bi, mir-122, or phosphatidylinositol-4 kinase III\u03b1 (PI4KIII\u03b1) inhibitors, prevent NS3-NS5B-mediated DMV formation. NS3-NS5B was unable to create DMVs in cyclophilin A (CypA) knockdown (KD) cells. We also found that the isomerase activity of CypA is absolutely required for DMV formation. This not only suggests that NS5A and CypA act in concert to build membranous viral factories but that CypI and NS5Ai mediate their early anti-HCV effects by preventing the formation of organelles, where HCV replication is normally initiated. This is the first investigation to examine the effect of a large panel of anti-HCV agents on DMV formation, and the results reveal that CypI and NS5Ai act at the same membranous web biogenesis step of HCV RNA replication, thus indicating a new therapeutic target of chronic hepatitis C.<\/jats:p>","DOI":"10.1128\/aac.04958-14","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T02:47:33Z","timestamp":1423536453000},"page":"2496-2507","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":56,"title":["Cyclophilin and NS5A Inhibitors, but Not Other Anti-Hepatitis C Virus (HCV) Agents, Preclude HCV-Mediated Formation of Double-Membrane-Vesicle Viral Factories"],"prefix":"10.1128","volume":"59","author":[{"given":"Udayan","family":"Chatterji","sequence":"first","affiliation":[{"name":"Department of Immunology &amp; Microbial Science, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bobardt","sequence":"additional","affiliation":[{"name":"Department of Immunology &amp; Microbial Science, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Immunology &amp; Microbial Science, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe A.","family":"Gallay","sequence":"additional","affiliation":[{"name":"Department of Immunology &amp; Microbial Science, The Scripps Research Institute, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.010"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2436"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.13.1.1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2008.068205"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.076646"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7150\/ijms.3.41","article-title":"Epidemiology of hepatitis C virus (HCV) infection","volume":"3","author":"Sy T","year":"2006","unstructured":"Sy T, Jamal MM. 2006. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 3:41\u201346.","journal-title":"Int J Med Sci"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.510260330","article-title":"Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group","volume":"26","author":"Tong MJ","year":"1997","unstructured":"Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, Hathcote EJ, White H, Foust RT, Jensen DM, Krawitt EL, Fromm H, Black M, Blatt LM, Klein M, Lubina J. 1997. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26:747\u2013754.","journal-title":"Hepatology"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371007"},{"key":"e_1_3_2_12_2","first-page":"911","article-title":"Cyclophilin inhibitors for the treatment of HCV infection","volume":"11","author":"Fischer G","year":"2010","unstructured":"Fischer G, Gallay P, Hopkins S. 2010. Cyclophilin inhibitors for the treatment of HCV infection. Curr Opin Investig Drugs 11:911\u2013918.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-011-8263-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-010-3140-2"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3410\/B4-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X10363055"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-16-7-303"},{"key":"e_1_3_2_18_2","first-page":"237","article-title":"Arrest all accessories\u2013inhibition of hepatitis C virus by compounds that target host factors","volume":"12","author":"von Hahn T","year":"2011","unstructured":"von Hahn T, Ciesek S, Manns MP. 2011. Arrest all accessories\u2013inhibition of hepatitis C virus by compounds that target host factors. Discov Med 12:237\u2013244.","journal-title":"Discov Med"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.03.020"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S30946"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22131"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.024"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.01.003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(09)60948-X"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22835"},{"key":"e_1_3_2_26_2","volume-title":"Once daily alisporivir (DEB025) plus PEG-IFN-alfa-2A\/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naive patients\u2014the ESSENTIAL study","author":"Flisiak R","year":"2011","unstructured":"Flisiak R, Pawlotsky JM, Crabbe R, Calistru PI, Kryczka W, Haussinger D, Mazzella G, Romero-Gomez M, Purcea D, Vuagniaux G, Bao W, Avila C, Zeuzem S. 2011. Once daily alisporivir (DEB025) plus PEG-IFN-alfa-2A\/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-naive patients\u2014the ESSENTIAL study, abstr 190. EASL 46th Annu Meet, 30 March to 3 April 2011, Berlin, Germany."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61416-0"},{"key":"e_1_3_2_28_2","volume-title":"Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study","author":"Pawlotsky JM","year":"2012","unstructured":"Pawlotsky JM, Sarin SK, Foster GR, Peng CY, Rasenack J, Flisiak R, Piratvisuth T, Wedemeyer H, Chuang WL, Zhang WM, Naoumov NV. 2012. Alisporivir plus ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study, abstr 233. 63rd Annu Meet Am Assoc Study Liver Dis, 9 to 12 November 2012, Boston, MA."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61417-2"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12360"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)60823-5"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.008"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02614-07"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.007625"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000546"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02550-08"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M809244200"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.041"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013687"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009815"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00393-11"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-10"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.182436"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001118"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1039\/c1md00227a"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00693-12"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3308"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.942282"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.5009\/gnl14083"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61059-X"},{"key":"e_1_3_2_51_2","volume-title":"Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial","author":"Kapoor R","year":"2014","unstructured":"Kapoor R, Kohli A, Sidharthan S, Sims Z, Petersen TL, Osinusi A, Nelson AK, Silk R, Kotb C, Sugarman K, Lam BP, Pang PS, Subramanian M, McHutchison JG, Masur H, Kottilil S, Rustgi VK. 2014. Treatment of hepatitis C genotype 4 with ledipasvir and sofosbuvir for 12 weeks: results of the SYNERGY trial, abstr 240. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_52_2","volume-title":"Interferon-free regimens of smbitasvir and ABT-450\/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results","author":"Pol S","year":"2014","unstructured":"Pol S, Reddy R, Hezode C, Hassanein T, Marcellin P, Berenguer M, Fleischer-Stepniewska K, Mobashery N, Hall C, Collins C, Vilchez R. 2014. Interferon-free regimens of smbitasvir and ABT-450\/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results, abstr 1928. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_53_2","volume-title":"Efficacy and safety of MK-5172 and MK-8742 \u00b1 ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: final results of the C-WORTHY study (parts A and B)","author":"Lawitz E","year":"2014","unstructured":"Lawitz E, Gane EJ, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib RH, Balart LA, Sund F, Lagging M, Dutko F, Howe A, Shaughnessy M, Hwang P, Wahl J, Robertson M, Barr E, Haber B. 2014. Efficacy and safety of MK-5172 and MK-8742 \u00b1 ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: final results of the C-WORTHY study (parts A and B), abstr 196. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_54_2","volume-title":"Efficacy and safety of MK-5172 + MK-8742 \u00b1 ribavirin in HCV mono-infected and HIV\/HCV co-infected treatment-naive, non-cirrhotic patients with HCV GT1 infection: the C-WORTHY study (final results, parts A and B)","author":"Sulkowski MS","year":"2014","unstructured":"Sulkowski MS, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourli\u00e8re M, DeJesus E, Zuckerman E, Dutko F, Howe A, Shaughnessy M, Hwang P, Wahl J, Robertson M, Barr E, Haber B. 2014. Efficacy and safety of MK-5172 + MK-8742 \u00b1 ribavirin in HCV mono-infected and HIV\/HCV co-infected treatment-naive, non-cirrhotic patients with HCV GT1 infection: the C-WORTHY study (final results, parts A and B), abstr 236. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_55_2","volume-title":"C-SWIFT: MK-5172 + MK-8742 + sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks","author":"Lawitz E","year":"2014","unstructured":"Lawitz E, Poordad F, Gutierrez JA, Evans B, Hwang P, Howe A, Feng HP, Robertson M, Wahl J, Barr E, Haber B. 2014. C-SWIFT: MK-5172 + MK-8742 + sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_3_2_57_2","volume-title":"Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-na\u00efve patients: a phase 2 \u201cproxy\u201d study","author":"Gane EJ","year":"2014","unstructured":"Gane EJ, Kocinsky H, Schwabe C, Mader M, Suri V, Donohue MK, Huang M, Hui J, Yang J, Apelian D. 2014. Interim sustained virologic response (SVR), safety and tolerability results of 8-week treatment with ACH-3102 and sofosbuvir in chronic hepatitis C (HCV), genotype-1 (GT-1), treatment-na\u00efve patients: a phase 2 \u201cproxy\u201d study, abstr LB-23. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_58_2","volume-title":"C-SWIFT: MK-5172 + MK-8742 + sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks","author":"Lawitz E","year":"2014","unstructured":"Lawitz E, Poordad F. 2014. C-SWIFT: MK-5172 + MK-8742 + sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks, abstr LB-33. 65th Annu Meet Am Assoc Study Liver Dis (AASLD), 7 to 12 November 2014, Boston, MA."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.376822"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00919-12"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088866"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.019"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03293-14"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.024"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902693106"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00059-11"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.194472"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002576"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01320-12"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M508175200"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00616-10"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178178"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm400781h"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1268"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(03)00134-4"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02460-05"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026300"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.21.13594-13605.2005"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01370-13"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003513"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00016-14"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003056"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.055"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5487-5492.2003"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00640-08"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01351-12"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.021"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000032"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000035"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.018531-0"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M404761200"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712380105"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801388105"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018917"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.12.018"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003359"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.002"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04958-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04958-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:58:38Z","timestamp":1645484318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04958-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1128\/AAC.04958-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04958-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"2014-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}